Through the 90-day period concluding December 12, 2025, Olema Pharmaceuticals's top three insider stakeholders include Director Andrew Rappaport (385.96K shares), Ch. Operating & Financial Off. Shane William Charles Kovacs (243.55K shares), Chief Business Officer Kinney Horn (2.46K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Capital Life Sciences Investors, Llc Bain | 4,300,000 | 13 Jan, 2025 | |
| Cyrus Harmon | 861,168 | 18 Sep, 2025 | |
| Biocapital Advisors Lp Paradigm | 783,118 | 05 Aug, 2024 | |
| G. Walmsley Graham | 700,761 | 18 Dec, 2024 | |
| David C. Myles | Ch. Discov. & Non Clin Dev Off | 598,333 | 11 Dec, 2024 |
| Partners L P/Il Bvf | 447,526 | 14 Jan, 2025 | |
| Andrew Rappaport | 385,965 | 25 Nov, 2025 | |
| Shane William Charles Kovacs | Ch. Operating & Financial Off. | 243,549 | 09 Dec, 2025 |
| Sean Bohen | President And CEO | 241,662 | 11 Dec, 2024 |
| Naseem Zojwalla | Chief Medical Officer | 129,509 | 17 Dec, 2024 |
| Kinney Horn | Chief Business Officer | 2,458 | 14 Mar, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 08 Dec, 2025 | Shane William Charles Kovacs | Common Stock | D | 75,000 | $0.00 | 243,549 | D | G |
| 26 Nov, 2025 | Shane William Charles Kovacs | Common Stock | D | 225,000 | $0.00 | 318,549 | D | G |
| 21 Nov, 2025 | Andrew Rappaport | Common Stock | A | 35,868 | $0.39 | 35,868 | D | M |
| 25 Nov, 2025 | Andrew Rappaport | Common Stock | D | 35,868 | $0.00 | 0 | D | G |
| 16 Sep, 2025 | Cyrus Harmon | - | - | 754,140 | D | |||
| 16 Sep, 2025 | Cyrus Harmon | Common Stock | D | 10,000 | $8.04 | 754,140 | D | S |
| 18 Sep, 2025 | Cyrus Harmon | - | - | 744,140 | D | |||
| 18 Sep, 2025 | Cyrus Harmon | Common Stock | D | 10,000 | $8.33 | 744,140 | D | S |
| 16 Sep, 2025 | Cyrus Harmon | Common Stock | D | 1,914 | $8.08 | 120,114 | I | S |
| 16 Sep, 2025 | Cyrus Harmon | - | - | 120,114 | I | |||
| 18 Sep, 2025 | Cyrus Harmon | Common Stock | D | 3,086 | $8.32 | 117,028 | I | S |
| 18 Sep, 2025 | Cyrus Harmon | - | - | 117,028 | I | |||
| 10 Jan, 2025 | Partners L P/Il Bvf | Common stock, $0.0001 par value | D | 235,450 | - | 2,655,977 | D | D |
| 10 Jan, 2025 | Partners L P/Il Bvf | - | - | 2,655,977 | D | |||
| 10 Jan, 2025 | Partners L P/Il Bvf | Common stock, $0.0001 par value | D | 161,810 | - | 2,003,966 | D | D |
| 10 Jan, 2025 | Partners L P/Il Bvf | - | - | 2,003,966 | D | |||
| 10 Jan, 2025 | Partners L P/Il Bvf | - | - | 347,970 | D | |||
| 10 Jan, 2025 | Partners L P/Il Bvf | Common stock, $0.0001 par value | D | 22,740 | - | 347,970 | D | D |
| 08 Jan, 2025 | Capital Life Sciences Investors, Llc Bain | - | - | 7,800,000 | I | |||
| 08 Jan, 2025 | Capital Life Sciences Investors, Llc Bain | Common Stock | A | 300,000 | $5.76 | 7,800,000 | I | P |